Metsera, Inc. Common Stock
MTSR
About: Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Employees: 109
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
327% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 11
322% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 9
37% more funds holding
Funds holding: 79 [Q1] → 108 (+29) [Q2]
17% more capital invested
Capital invested by funds: $1.49B [Q1] → $1.74B (+$252M) [Q2]
6.27% more ownership
Funds ownership: 51.89% [Q1] → 58.17% (+6.27%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
40% less call options, than puts
Call options by funds: $1.62M | Put options by funds: $2.69M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Leerink Partners
David Risinger
|
$77
|
Outperform
Initiated
|
9 Sep 2025 |
|
B of A Securities
Tim Anderson
|
$50
|
Buy
Maintained
|
28 Aug 2025 |
|
Wells Fargo
Cerena Chen
|
$65
|
Overweight
Initiated
|
20 Jun 2025 |
Financial journalist opinion
